All In Biotech

Drug Trial Radar · NCT06095505

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 8, 2024

Primary completion

Oct 30, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Puma Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.

Conditions

  • Small Cell Lung Cancer

Interventions

  • AlisertibDrug

    Alisertib enteric-coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) within biomarker-defined subgroupTime frame: From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months
  2. Duration of response (DOR) within biomarker-defined subgroupTime frame: From start date of response (after date of first dose) to first PD, assessed up to 36 months
  3. Disease Control Rate (DCR) within biomarker-defined subgroupTime frame: From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 36 months
  4. Progression Free Survival (PFS) within biomarker-defined subgroupTime frame: From date of first dose to date of recurrence, progression or death, assessed up to 36 months
  5. Overall Survival (OS) within biomarker-defined subgroupTime frame: From date of first dose to death, assessed up to 36 months

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Daphne, Alabama · Recruiting

  • The Oncology Institute of Hope and Innovation

    Long Beach, California · Recruiting

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Georgetown Lombardi Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • The Oncology Institute of Hope and Innovation

    Fort Lauderdale, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Illinois Cancer Specialists

    Niles, Illinois · Recruiting

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana · Recruiting

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Completed

  • Minnesota Oncology Hematology

    Burnsville, Minnesota · Recruiting

  • Nebraska Cancer Specialists

    Grand Island, Nebraska · Recruiting

  • Oncology Hematology Care Clinical Trials

    Cincinnati, Ohio · Recruiting

  • University Hospital - Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Active not recruiting

  • Zangmeister Cancer Center

    Columbus, Ohio · Recruiting

  • Oncology Associates of Oregon

    Eugene, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Withdrawn

  • Medical University of South Carolina Hollings Cancer Center

    Charleston, South Carolina · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Oncology & Hematology Associates of Southwest Virginia

    Blacksburg, Virginia · Recruiting

  • Universtity of Virginia Health System

    Charlottesville, Virginia · Completed

  • Virginia Cancer Specialists Research Institute

    Fairfax, Virginia · Recruiting

  • Northwest Cancer Specialists

    Vancouver, Washington · Recruiting

  • Marshfield Medical Center

    Marshfield, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.